Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs BIOAF


Primary Symbol: V.BTI.H

Healthcare Biotechnology
Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs > beenthere Responds to My Post
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(2261)
•••
Comment by Boomskidon Aug 23, 2023 10:56pm
67 Views
Post# 35603080

RE:RE:beenthere Responds to My Post

RE:RE:beenthere Responds to My PostBwahhhh hahahahahahaha!

So it was a fix! A short-loan-tax play by Sappy Capital, I mean, LT-Sabby Capital.

What, couldn't they decide how to screw Bioasis?

And Rathjen fell for it?

And the lawyers missed it?

And the 460-page information circular didn't disclose anything?

No wait. It was Ladenberg Thalmann. 

They shorted Bioasis?

Lemme go look for the volume of shorts that would be an LT Sappy play. Nnnnnnnnope. Nothing there.

Where was the loan part of it, by LT?

Lind was LT's agent? Lind hasn't acted on the debt yet.

Sappy Cap. Bwahhhh hahahahahahaha!

Founder Hal Mintz charged with securies violations, serious ones, in June.

Friend of yours, TT?

Say, why didn't you expose the LT-Sappy Cap play while it was happening?

That's the problem with blind hate.

Makes ya stoopid.

jd
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities